参考文献/References:
[1] Sobecki M, Mrouj K, Colinge J, et al. Cell-cycle regulation
accounts for variability in Ki-67 expression levels [J].
Cancer Res, 2017, 77(10): 2722-2734.
[2] Schlüter C, Duchrow M, Wohlenberg C, et al. The cell proli-
feration-associated antigen of antibody Ki-67: a very large,
ubiquitous nuclear protein with numerous repeated
elements, representing a new kind of cell cycle-maintaining
proteins [J]. J Cell Biol, 1993, 123(3): 513-522.
[3] Sun X, Kaufman PD. Ki-67: more than a proliferation
marker [J]. Chromosoma, 2018, 127(2): 175-186.
[4] Booth DG, Earnshaw WC. Ki-67 and the chromosome
periphery compartment in mitosis [J]. Trends Cell Biol,
2017, 27(12): 906-916.
[5] Cuylen S, Blaukopf C, Politi A Z, et al. Ki-67 acts as a
biological surfactant to disperse mitotic chromosomes [J].
Nature, 2016, 535(7611): 308-312.
[6] Sobecki M, Mrouj K, Camasses A, et al. The cell prolifera-
tion antigen Ki-67 organises heterochromatin [J]. ELife,
2016, 5: e13722.
[7] Kametaka A, Takagi M, Hayakawa T, et al. Interaction of
the chromatin compaction-inducing domain (LR domain) of
Ki-67 antigen with HP1 proteins[J]. Genes Cells, 2002, 7
(12): 1231-42.
[8] Saksouk NSE, Déjardin J. Constitutive heterochromatin
formation and transcription in mammals [J]. Epigenetics
Chromatin, 2015, 8: 3.
[9] Gerdes JSU, Lemke H, Stein H. Production of a mouse
monoclonal antibody reactive with a human nuclear antigen
associated with cell proliferation [J]. Int J Cancer, 1983, 31
(1): 13-20.
[10] Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a
cell proliferation-associated human nuclear antigen defined
by the monoclonal antibody Ki-67 [J]. J Immunol, 1984,
133(4): 1710-1715.
[11] Ishida S, Huang E, Zuzan H, et al. Role for E2F in control of
both DNA replication and mitotic functions as revealed
from DNA microarray analysis [J]. Mol Cell Biol, 2001, 21
(14): 4684-4699.
[12] Chierico L, Rizzello L, Guan L, et al. The role of the two
splice variants and extranuclear pathway on Ki-67 regula-
tion in non-cancer and cancer cells [J]. PLoS One, 2017, 12
(2): e0171815.
[13] Tian H, Qian GW, Li W, et al. A critical role of Sp1 trans-
cription factor in regulating the human Ki-67 gene expres-
sion [J]. Tumour Biol, 2011, 32(2): 273-283.
[14] Wang MJ, Pei DS, Qian GW, et al. p53 regulates Ki-67
promoter activity through p53- and Sp1-dependent manner
in HeLa cells [J]. Tumour Biol, 2011, 32(5): 905-912.
[15] Stamatiou K, Vagnarelli P. Chromosome clustering in mito-
sis by the nuclear protein Ki-67 [J]. Biochem Soc Trans,
2021, 49(6): 2767-2776.
[16] Cuylen-Haering S, Petrovic M, Hernandez-Armendariz A,
et al. Chromosome clustering by Ki-67 excludes cytoplasm
during nuclear assembly [J]. Nature, 2020, 587(7833): 285-
290.
[17] Perry A, Wesseling P. Histologic classification of gliomas
[J]. Handb Clin Neurol, 2016, 134: 71-95.
[18] Wesseling P, Capper D. WHO 2016 Classification of gliomas
[J]. Neuropathol Appl Neurobiol, 2018, 44(2): 139-150.
[19] Qu DW, Xu HS, Han XJ, et al. Expression of cyclinD1 and
Ki-67 proteins in gliomas and its clinical significance [J].
Eur Rev Med Pharmacol Sci, 2014, 18(4): 516-519.
[20] Cai J, Yang P, Zhang C, et al. ATRX mRNA expression
combined with IDH1/2 mutational status and Ki-67
expression refines the molecular classification of astrocytic
tumors: evidence from the whole transcriptome sequencing
of 169 samples samples [J]. Oncotarget, 2014, 5(9): 2551-
2561.
[21] Wang PF, Liu N, Song HW, et al. IDH-1 R132H mutation
status in diffuse glioma patients: implications for classifica-
tion [J]. Oncotarget, 2016, 7(21): 31393-31400.
[22] Ryken TC, Parney I, Buatti J, et al. The role of radiotherapy
in the management of patients with diffuse low grade
glioma: a systematic review and evidence-based clinical
practice guideline [J]. J Neurooncol, 2015, 125(3): 551-583.
[23] Chen WJ, He DS, Tang RX, et al. Ki-67 is a valuable
prognostic factor in gliomas: evidence from a systematic
review and meta-analysis [J]. Asian Pac J Cancer Prev,
2015, 16(2): 411-420.
[24] Chaloob MH, Qasim BJ, Mohammed AA. Immunohisto-
chemical expression of Ki-67, PCNA and CD34 in astrocy-
tomas: a clinicopathological study [J]. Oman Med J, 2012,
27(5): 368-374.
[25] Nielsen LG, Bangso JA, Lindahl KH, et al. Evaluation of the
proliferation marker Ki-67 in gliomas: interobserver varia-
bility and digital quantification [J]. Diagn Pathol, 2018, 13
(1): 38.
[26] Gillies RKP, Hricak H. Radiomics: images are more than
pictures, they are data [J]. Radiology, 2016, 278(2): 563-
577.
[27] Thawani R, Mclane M, Beig N, et al. Radiomics and radio-
genomics in lung cancer: a review for the clinician [J]. Lung
Cancer, 2018, 115: 34-41.
[28] Um H, Tixier F, Bermudez D, et al. Impact of image prepro-
cessing on the scanner dependence of multi-parametric
MRI radiomic features and covariate shift in multi-institu-
tional glioblastoma datasets [J]. Phys Med Biol, 2019, 64
(16): 165011.
[29] Stringfield O, Arrington JA, Johnston SK, et al. Multipara-
meter MRI predictors of long-term survival in glioblastoma
multiforme [J]. Tomography, 2019, 5(1): 135-144.
[30] Van Der Velden BHM, Van Rijssel MJ, Lena B, et al. Har-
monization of quantitative parenchymal enhancement in
T1-weighted breast MRI [J]. J Magn Reson Imaging, 2020,
52(5): 1374-1382.
[31] Zhou M, Scott J, Chaudhury B, et al. Radiomics in brain
tumor: image assessment, quantitative feature descriptors,
and machine-learning approaches [J]. AJNR Am J Neuro-
radiol, 2018, 39(2): 208-216.
[32] Tiwari P, Prasanna P, Wolansky L, et al. Computer-extract-
ed texture features to distinguish cerebral radionecrosis
from recurrent brain tumors on multiparametric MRI: a
feasibility study [J]. AJNR Am J Neuroradiol, 2016, 37(12):
2231-2236.
[33] Pereira S, Pinto A, Alves V, et al. Brain tumor segmentation
using convolutional neural networks in MRI images [J].
IEEE Trans Med Imaging, 2016, 35(5): 1240-1251.
[34] Suter Y, Knecht U, Alao M, et al. Radiomics for glioblastoma
survival analysis in pre-operative MRI: exploring feature
robustness, class boundaries, and machine learning techni-
ques [J]. Cancer Imaging, 2020, 20(1): 55.
[35] Wang K, Lu X, Zhou H, et al. Deep learning radiomics of
shear wave elastography significantly improved diagnostic
performance for assessing liver fibrosis in chronic hepatitis
B: a prospective multicentre study [J]. Gut, 2019, 68(4):
729-741.
[36] Tian Q, Yan LF, Zhang X, et al. Radiomics strategy for
glioma grading using texture features from multiparametric
MRI [J]. J Magn Reson Imaging, 2018, 48(6): 1518-1528.
[37] Suh HB, Choi YS, Bae S, et al. Primary central nervous
system lymphoma and atypical glioblastoma: differentiation
using radiomics approach [J]. Eur Radiol, 2018, 28(9):
3832-3839.
[38] Han L, Wang S, Miao Y, et al. MRI texture analysis based
on 3D tumor measurement reflects the IDH1 mutations in
gliomas--a preliminary study [J]. Eur J Radiol, 2019, 112:
169-179.
[39] Kickingereder P, Burth S, Wick A, et al. Radiomic profiling
of glioblastoma: identifying an imaging predictor of patient
survival with improved performance over established
clinical and radiologic risk models [J]. Radiology, 2016, 280
(3): 880-889.
[40] Liu X, Li Y, Qian Z, et al. A radiomic signature as a non-
invasive predictor of progression-free survival in patients
with lower-grade gliomas [J]. Neuroimage Clin, 2018, 20:
1070-1077.
[41] Kickingereder P, Gotz M, Muschelli J, et al. Large-scale
radiomic profiling of recurrent glioblastoma identifies an
imaging predictor for stratifying anti-angiogenic treatment
response [J]. Clin Cancer Res, 2016, 22(23): 5765-5771.
[42] Su C, Jiang J, Zhang S, et al. Radiomics based on multicon-
trast MRI can precisely differentiate among glioma subtypes
and predict tumour-proliferative behaviour [J]. Eur Radiol,
2019, 29(4): 1986-1996.
[43] Su C, Chen X, Liu C, et al. T2-FLAIR, DWI and DKI
radiomics satisfactorily predicts histological grade and
Ki-67 proliferation index in gliomas [J]. Am J Transl Res,
2021, 13(8): 9182-9194.
[44] Lin ZX. Glioma-related edema: new insight into molecular
mechanisms and their clinical implications [J]. Chin J
Cancer, 2013, 32(1): 49-52.
[45] Yamahara T, Numa Y, Oishi T, et al. Morphological and
flow cytometric analysis of cell infiltration in glioblastoma:
a comparison of autopsy brain and neuroimaging [J]. Brain
Tumor Pathol, 2010, 27(2): 81-87.
[46] Sun X, Pang P, Lou L, et al. Radiomic prediction models for
the level of Ki-67 and p53 in glioma [J]. J Int Med Res,
2020, 48(5): 300060520914466.
[47] Li Y, Qian Z, Xu K, et al. Radiomic features predict Ki-67
expression level and survival in lower grade gliomas [J]. J
Neurooncol, 2017, 135(2): 317-324.
相似文献/References:
[1]常英男 王 策 赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛 克 陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许 耿 路俊锋 杨 忠 施建斌 吴秋月 王 烨 庄冬晓 吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(05):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰 陈银生 赛 克 张湘衡 柯 超 杨群英 牟永告 许海雄 陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(05):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波 杨宇焦 张 逵 范润金 张 渊 杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性
癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(05):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚 成于思 王 辉 汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞
增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(05):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林 雨 张 恺 李 帅 杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]戴黎明 徐成仕 王泽芬 曹长军 李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(05):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[9]彭泽生 田道锋 张申起 陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(05):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[10]冯 驰 郭双毅 程龙海 罗 杰.氯喹通过抑制自噬促进TRAIL诱导的胶质瘤细胞凋亡[J].中国临床神经外科杂志,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
FENG Chi,GUO Shuang-yi,CHENG Long-hai,et al.Chloroquine promotes TRAIL-induced apoptosis of glioma cells through inhibition of autophagy[J].,2016,(05):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
[11]龙治豪 连海伟 邢变枝 刘仁忠.MRI影像组学模型预测脑胶质瘤IDH-1基因突变和Ki-67表达水平的价值[J].中国临床神经外科杂志,2022,27(04):255.[doi:10.13798/j.issn.1009-153X.2022.04.005]
LONG Zhi-hao,LIAN Hai-wei,XING Bian-zhi,et al.Clinical value of MRI T2WI-based radiomics model in prediction of IDH-1 genotype and Ki-67 expression level in gliomas[J].,2022,27(05):255.[doi:10.13798/j.issn.1009-153X.2022.04.005]